がん用生物学的製剤の世界市場レポート 2024年

がん用生物学的製剤の市場規模は、今後数年間で急速に成長すると予想されます。 2028年には9.6%の年間複合成長率（CAGR）で1,687億5,000万米ドルに成長すると予想されます。今後の成長が予想されるのは、いくつかの要因によるものと考えられます。これらには、既存のがん用生物学的製剤の適応症の拡大、治療効果を高めるための併用療法の開発と利用、治療の決定に情報を提供するための現実世界の証拠の利用の拡大、がん治療に有望な道を提供する遺伝子治療と細胞治療の進歩が含まれます。

慢性疾患の有病率の上昇傾向は、がん用生物学的製剤市場の成長を推進する重要な原動力となっています。慢性疾患は長期間にわたって持続し、人々の健康や幸福に影響を及ぼすことが多く、がんは最も蔓延している慢性疾患の1つです。特に、一般的ながんには、乳がん、肺がん、前立腺がん、結腸がん、直腸がん、皮膚黒色腫、膀胱がん、非ホジキンリンパ腫、腎臓がん、子宮内膜がん、白血病、膵臓がん、甲状腺がん、肝臓がんなどがあります。国立バイオテクノロジー情報センターは、2023年 1月までに慢性疾患を患っている50歳以上の人の数が大幅に増加し、米国では2020年の7,152万2,000人から2050年までに1億4,266万人に達すると予測しています。慢性疾患の蔓延は、予見可能な将来においてがん用生物学的製剤市場の成長軌道を導く準備ができています。

がん研究に向けられた投資の急増は、がん用生物学的製剤市場の拡大を促進する触媒として機能すると予測されています。がん研究への投資は、がんの包括的な理解、予防、診断、治療を目的とした科学的取り組みに向けられた財政的支援を意味します。この分野での資金強化により、製薬企業やバイオテクノロジー企業は、薬物標的の同定や潜在的な候補合成など、先駆的な発見、厳密な試験、新規がん用生物学的製剤の開発に取り組むことができるようになります。たとえば、2022年 3月、オーストラリアに本拠を置く政府機関である保健高齢者ケア省は、がんサービスと転帰の強化に8億9,350万米ドルを割り当てました。この投資の一部である約3億2,940万米ドルは、さまざまな種類のがん向けに設計されたトロデルビー、リムパーザ、マイロターグなどの新しいがん治療薬の導入を支援し、毎年かなりの数の患者に恩恵をもたらしています。したがって、がん研究への投資の増加により、がん用生物学的製剤市場の成長が今後も促進されると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のがん用生物製剤市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のがん用生物学的製剤市場規模実績と成長、2018～2023年
• 世界のがん用生物学的製剤市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のがん用生物製剤市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• モノクローナル抗体
• ワクチン
• 細胞と遺伝子治療
• その他
• 世界のがん用生物製剤市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 非小細胞肺がん
• 前立腺がん
• 乳がん
• 急性骨髄性白血病
• リンパ腫
• 多発性骨髄腫
• 卵巣がん
• 結腸直腸がん
• 胃がん
• その他
• 世界のがん用生物学的製剤市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• クリニック
• その他

第7章 地域と国の分析

• 世界のがん用生物学的製剤市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のがん用生物学的製剤市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん用生物学的製剤市場の競合情勢
• がん用生物学的製剤市場の企業プロファイル
  • AbbVie Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

Cancer biologics encompass substances derived from living organisms or their byproducts, utilized in the prevention, detection, or treatment of cancer and related disorders. These agents include immunoglobulins, interleukins, and vaccines among others. Biological therapy, a cancer treatment method, harnesses the body's immune system to combat cancer cells effectively.

The primary categories of cancer biologics consist of monoclonal antibodies, vaccines, cell and gene therapy, and other specialized therapies. Monoclonal antibodies, developed through cloning a single white blood cell, originate from a singular parent cell and have widespread application in various cancer types such as non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancer, and more. These biologics are distributed through diverse channels including hospitals, clinics, and other healthcare facilities to aid in cancer treatment and care.

The cancer biologics market research report is one of a series of new reports from The Business Research Company that provides cancer biologics market statistics, including cancer biologics industry global market size, regional shares, competitors with a cancer biologics market share, detailed cancer biologics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biologics industry. This cancer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer biologics market size has grown rapidly in recent years. It will grow from $106.2 billion in 2023 to $117.03 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed in the historical period can be attributed to several key factors. These include the escalating incidence of cancer cases worldwide, a heightened awareness and understanding of the benefits of cancer biologics among healthcare professionals and patients, advancements leading to improved efficacy and safety profiles of these biologics, regulatory approvals for new cancer biologics expanding treatment options, and a growing acknowledgment and utilization of combination therapies for cancer treatment. These elements collectively contributed to the growth and acceptance of cancer biologics, fostering their increased adoption in cancer care and treatment protocols.

The cancer biologics market size is expected to see rapidly grown in the next few years. It will grow to $168.75 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the forthcoming period can be attributed to several contributing factors. These include the expansion of indications for existing cancer biologics, the development and utilization of combination therapies to enhance treatment effectiveness, the growing utilization of real-world evidence to inform treatment decisions, and advancements in gene and cell therapies, offering promising avenues in cancer care.

The upward trend in chronic disease prevalence stands as a key driver in propelling the growth of the cancer biologics market. Chronic diseases, persisting over extended periods, often affect people's health and wellbeing, with cancer being one of the most prevalent chronic conditions. Notably, common cancers include breast, lung, prostate, colon, rectum, skin melanoma, bladder, non-Hodgkin lymphoma, kidney, endometrial, leukemia, pancreatic, thyroid, and liver cancers. By January 2023, the National Center for Biotechnology Information projects a significant surge in the number of individuals aged 50 years and older experiencing chronic illnesses, expected to reach 142.66 million by 2050 in the United States, up from 71.522 million in 2020. This escalation in chronic disease prevalence is poised to steer the cancer biologics market's growth trajectory in the foreseeable future.

The upsurge in investments directed towards cancer research is predicted to act as a catalyst in driving the expansion of the cancer biologics market. Investments in cancer research denote financial backing channeled towards scientific endeavors aimed at comprehensively understanding, preventing, diagnosing, and treating cancer. Heightened funding in this domain empowers pharmaceutical and biotechnology entities to delve into pioneering discoveries, rigorous testing, and development of novel cancer biologics, including drug target identification and potential candidate synthesis. For instance, in March 2022, the Australian-based government agency, the Department of Health and Aged Care, allocated $893.5 million to bolster cancer services and outcomes. Part of this investment, around $329.4 million, supports the introduction of new cancer medications like Trodelvy, Lynparza, and Mylotarg, designed for various cancer types, benefiting a substantial number of patients annually. Consequently, increased investment in cancer research is expected to propel the growth of the cancer biologics market moving forward.

Entities within the cancer biologics market are actively engaged in developing predictive biomarkers, aiding physicians in treatment decisions by leveraging physiological indicators for performance prediction. Predictive biomarkers meticulously examine tumor growth in patients by scrutinizing major causative factors, given the distinct etiology of cancer among individuals. These biomarkers serve not only in early cancer detection but also in determining the most cost-effective treatment approaches, especially concerning biologics rooted in gene therapy.

Major players in the cancer biologics market are intensively focused on crafting cancer biosimilars, exemplified by ONTRUZAN, to secure a competitive edge. ONTRUZAN, a biosimilar drug, is specifically formulated to address various cancer forms, encompassing breast and gastric cancer treatments. In November 2022, Organon, a Canada-based women's health firm, launched ONTRUZAN, a Herceptin biosimilar, broadening the therapeutic options for Canadian adults confronting early breast cancer (EBC), metastatic breast cancer (MBC), and metastatic gastric cancer (MGC). This strategic inclusion of biosimilars into breast and gastric cancer treatments aims to expand access to cost-effective medications, thereby fostering avenues for continual reinvestment in healthcare system innovations.

In November 2022, Biocon Biologics Ltd., an esteemed biopharmaceutical company based in India, successfully acquired the global biosimilars business situated in North America from Viatris Inc., a prominent global pharmaceutical and healthcare corporation. The specific financial details of the transaction remain undisclosed. This strategic acquisition represents Biocon's strategic move to strengthen its position within the global biosimilars market, enabling the company to provide comprehensive end-to-end solutions to a wide spectrum of patients and customers worldwide. Viatris Inc., recognized as a US-based global pharmaceutical and healthcare corporation, has specialized expertise in cancer biologics, and this acquisition is expected to augment Biocon's capabilities and further its reach in the biosimilars domain, reinforcing its commitment to advancing healthcare solutions across the globe.

Major companies operating in the cancer biologics market include AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer inc., Celgene Corporation, Serum Institute of India Pvt. Ltd., Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc., Stryker Corporation, Terumo Corporation

North America was the largest region in the cancer biologics market in 2023. The Middle East is expected to be the fastest growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The cancer biologics market consists of sales of cancer vaccines, cytokine therapy, and angiogenesis inhibitors. Values in this market are factory gate values which are the values of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer biologics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Monoclonal Antibodies; Vaccines; Cell And Gene Therapy; Other Types
• 2) By Application: Non-small Cell Lung Cancer; Prostate Cancer; Breast Cancer; Acute Myeloid Leukemia; Lymphoma; Multiple Myeloma; Ovarian Cancer; Colorectal Cancer; Gastric Cancers; Other Applications
• 3) By Distribution Channel: Hospitals; Clinics; Other Distribution Channels
• Companies Mentioned: AbbVie Inc.; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Eli Lilly and Company; AmgenInc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Biologics Market Characteristics

3. Cancer Biologics Market Trends And Strategies

4. Cancer Biologics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Cancer Biologics Market Size and Growth

• 5.1. Global Cancer Biologics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Cancer Biologics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Cancer Biologics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Biologics Market Segmentation

• 6.1. Global Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monoclonal Antibodies
• Vaccines
• Cell And Gene Therapy
• Other Types
• 6.2. Global Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Colorectal Cancer
• Gastric Cancers
• Other Applications
• 6.3. Global Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Other Distribution Channels

7. Cancer Biologics Market Regional And Country Analysis

• 7.1. Global Cancer Biologics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Cancer Biologics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Biologics Market

• 8.1. Asia-Pacific Cancer Biologics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Biologics Market

• 9.1. China Cancer Biologics Market Overview
• 9.2. China Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Biologics Market

• 10.1. India Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Biologics Market

• 11.1. Japan Cancer Biologics Market Overview
• 11.2. Japan Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Biologics Market

• 12.1. Australia Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Biologics Market

• 13.1. Indonesia Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Biologics Market

• 14.1. South Korea Cancer Biologics Market Overview
• 14.2. South Korea Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Biologics Market

• 15.1. Western Europe Cancer Biologics Market Overview
• 15.2. Western Europe Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Biologics Market

• 16.1. UK Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Biologics Market

• 17.1. Germany Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Biologics Market

• 18.1. France Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Biologics Market

• 19.1. Italy Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Biologics Market

• 20.1. Spain Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Biologics Market

• 21.1. Eastern Europe Cancer Biologics Market Overview
• 21.2. Eastern Europe Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Biologics Market

• 22.1. Russia Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Biologics Market

• 23.1. North America Cancer Biologics Market Overview
• 23.2. North America Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Biologics Market

• 24.1. USA Cancer Biologics Market Overview
• 24.2. USA Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Biologics Market

• 25.1. Canada Cancer Biologics Market Overview
• 25.2. Canada Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Biologics Market

• 26.1. South America Cancer Biologics Market Overview
• 26.2. South America Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Biologics Market

• 27.1. Brazil Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Biologics Market

• 28.1. Middle East Cancer Biologics Market Overview
• 28.2. Middle East Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Biologics Market

• 29.1. Africa Cancer Biologics Market Overview
• 29.2. Africa Cancer Biologics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Cancer Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Cancer Biologics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Biologics Market Competitive Landscape And Company Profiles

• 30.1. Cancer Biologics Market Competitive Landscape
• 30.2. Cancer Biologics Market Company Profiles
  • 30.2.1. AbbVie Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. GlaxoSmithKline plc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Eli Lilly and Company
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
• 30.2.5.
• 30.2.5.1. Overview
• 30.2.5.2. Products and Services
• 30.2.5.3. Strategy
• 30.2.5.4. Financial Performance

31. Global Cancer Biologics Market Competitive Benchmarking

32. Global Cancer Biologics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Cancer Biologics Market

34. Cancer Biologics Market Future Outlook and Potential Analysis

• 34.1 Cancer Biologics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Cancer Biologics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Cancer Biologics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer